Open AccessResponse to lorlatinib on a patient with ALK ‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
Author(s) -
Kobayashi Takashi,
Kanda Shintaro,
Fukushima Toshirou,
Noguchi Takuro,
Sekiguchi Nodoka,
Koizumi Tomonobu
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14056
Subject(s) - crizotinib , alectinib , anaplastic lymphoma kinase , ceritinib , medicine , alk inhibitor , lung cancer , metastasis , cancer research , mutation , brain metastasis , cancer , pathology , gene , biology , genetics , malignant pleural effusion
Abstract We describe a case of an anaplastic lymphoma kinase ( ALK )‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance.